TR200003048T2 - İnsülinin peptit analoglarının diyabet tedavisi için kullanımı. - Google Patents

İnsülinin peptit analoglarının diyabet tedavisi için kullanımı.

Info

Publication number
TR200003048T2
TR200003048T2 TR2000/03048T TR200003048T TR200003048T2 TR 200003048 T2 TR200003048 T2 TR 200003048T2 TR 2000/03048 T TR2000/03048 T TR 2000/03048T TR 200003048 T TR200003048 T TR 200003048T TR 200003048 T2 TR200003048 T2 TR 200003048T2
Authority
TR
Turkey
Prior art keywords
diabetes
treatment
peptide analogues
insulin peptide
peptide analogs
Prior art date
Application number
TR2000/03048T
Other languages
English (en)
Inventor
Gaur Amitabh
Ling Nicholas
J. Conlon Paul
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of TR200003048T2 publication Critical patent/TR200003048T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Bu bulus, genel olarak dogal (B) zinciri dizisinin artiklarini (9-23) içeren peptitlerden türetilen insülin (B) zincirinin peptit analoglarina yöneliktir. Analoglar, konum (12, 13, 15) ve/veya (16)'da dogal diziden degisiklik gösterirler ve ayrica konum (19)'da ve/veya diger konumlarda da degisiklik gösterebilirler. Bu peptit analoglarini içeren farmasötik bilesimler saglanmistir. Peptit analoglari, diyabet gelisiminin tedavi edilmesinde ve önlenmesinde faydalidirlar.
TR2000/03048T 1998-02-23 1999-02-23 İnsülinin peptit analoglarının diyabet tedavisi için kullanımı. TR200003048T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2815698A 1998-02-23 1998-02-23

Publications (1)

Publication Number Publication Date
TR200003048T2 true TR200003048T2 (tr) 2000-12-21

Family

ID=21841884

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03048T TR200003048T2 (tr) 1998-02-23 1999-02-23 İnsülinin peptit analoglarının diyabet tedavisi için kullanımı.

Country Status (20)

Country Link
US (1) US6197926B1 (tr)
EP (1) EP1056776A1 (tr)
JP (1) JP2002504491A (tr)
KR (1) KR20010041238A (tr)
CN (1) CN1241942C (tr)
AP (1) AP2000001888A0 (tr)
AU (1) AU741037B2 (tr)
BR (1) BR9908178A (tr)
CA (1) CA2321929A1 (tr)
EA (1) EA003944B1 (tr)
HU (1) HUP0100928A3 (tr)
ID (1) ID26788A (tr)
IL (1) IL137904A0 (tr)
NO (1) NO20004198L (tr)
NZ (1) NZ506447A (tr)
OA (1) OA11453A (tr)
PL (1) PL342517A1 (tr)
SK (1) SK12412000A3 (tr)
TR (1) TR200003048T2 (tr)
WO (1) WO1999042482A1 (tr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562942B1 (en) * 1999-02-23 2003-05-13 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
WO2001085154A2 (en) * 2000-05-12 2001-11-15 Oregon Health Sciences University Method of treating immune pathologies with low dose estrogen
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
US8987263B2 (en) 2002-10-10 2015-03-24 Meir Shinitzky Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
CA2527830A1 (en) * 2003-06-02 2004-12-23 Mercia Pharma, Inc. Therapeutic vaccine compositions for the treatment of type 1 diabetes
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
JP5789515B2 (ja) * 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
US12370251B2 (en) 2009-11-05 2025-07-29 Mercia Pharma, Inc. Adjuvanted nanoparticulate influenza vaccine
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US20110311536A1 (en) * 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
JP5969469B2 (ja) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
EP2585102B1 (en) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN111925420B (zh) * 2019-12-11 2022-04-01 山东大学 一种多肽作为嗅觉受体Olfr109激动剂配体的应用
USD1043348S1 (en) * 2021-09-24 2024-09-24 H.J. Heinz Company Brands Llc Bottle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5594100A (en) * 1995-02-22 1997-01-14 Regents Of The University Of Colorado Epitope for prevention of type I diabetes
EP0835129B1 (en) * 1995-06-30 2003-10-29 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes

Also Published As

Publication number Publication date
SK12412000A3 (sk) 2002-05-09
EP1056776A1 (en) 2000-12-06
BR9908178A (pt) 2002-01-15
US6197926B1 (en) 2001-03-06
WO1999042482A1 (en) 1999-08-26
HUP0100928A3 (en) 2001-11-28
OA11453A (en) 2003-12-08
JP2002504491A (ja) 2002-02-12
HUP0100928A2 (hu) 2001-08-28
KR20010041238A (ko) 2001-05-15
NO20004198L (no) 2000-10-20
AU2783199A (en) 1999-09-06
CN1294597A (zh) 2001-05-09
AP2000001888A0 (en) 2000-09-30
ID26788A (id) 2001-02-08
EA003944B1 (ru) 2003-10-30
CA2321929A1 (en) 1999-08-26
NO20004198D0 (no) 2000-08-22
CN1241942C (zh) 2006-02-15
IL137904A0 (en) 2001-10-31
PL342517A1 (en) 2001-06-18
EA200000872A1 (ru) 2001-02-26
NZ506447A (en) 2002-11-26
AU741037B2 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
TR200003048T2 (tr) İnsülinin peptit analoglarının diyabet tedavisi için kullanımı.
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
ATE266043T1 (de) Peptidanaloge des menschlichen basischen myelinproteins
RU2214418C2 (ru) Аналоги glp-1
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
TR200000649T2 (tr) PTHrP analogları kullanılarak kırıkların iyileştirilmesi.
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
ATE212846T1 (de) Bisphosphonat und anti-resorption agentien, enthaltende zusammensetzungen zur hemmung der knochenschwund
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
TR199501630A2 (tr) Peptid p277 benzerleri ve diagnoz ve dibetlerin'lerin tedavisi icin onlari iceren kompozisyonlar.
ES2180948T3 (es) Peptido que proviene de una forma soluble de la acetilcolinesterasa, activo como modulador del canal.
CY1105452T1 (el) Παραγωγα της κυκλοσπορινης και μεθοδος παρασκευης των εν λογω παραγωγων
NZ235497A (en) Peptides (possibly related to hirudin) and pharmaceutical compositions for reducing blood coagulation
ATE390440T1 (de) Neuroaktive peptide
DE69434151D1 (de) Therapeutische inhaltsstoffe
DK0423326T3 (da) Hidtil ukendt fysiologisk aktivt peptid og calcium-metabolisme-regulerende middel, der omfatter peptidet som effektiv besta
ATE283276T1 (de) Deoxyhypusin reagenz und peptide
DK1158050T3 (da) Human cysteinyl-leukotrienreceptor (CysLT2)